COMPPARE Newsletter: Spring/Summer 2022

A Message from Dr. Nancy Mendenhall

As we near the completion of COMPPARE’s overall enrollment objective – a total of 3,000 patients – we are beginning to reflect and evaluate what we’ve learned thus far in creating and carrying out a large, multi-institutional pragmatic trial. Read Dr. Mendenhall’s message.

Partner Site Spotlight: The Duke Cancer Center

The Duke Cancer Center, designated as a comprehensive cancer center by the NCI in 1973, treated more than 66,000 patients last year and received over $115 million in cancer research funding. – follow the conversation here.

COMPPARE Achieves 75% Enrollment Milestone

COMPPARE realized both a remarkable overall accrual rate and a exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. – read about this important achievement.

COMPPARE Enrolls 1,500th Proton Patient

The study has closed enrollment for the proton cohort. This goal was achieved in advance of the projected completion date of July 31, 2022- learn more.

Your Diet and Prostate Health

Proton BOB’s own Bob Marckini discusses diet and lifestyle recommendations and a checklist of foods and activities that could be easily incorporated into the daily routines of prostate cancer patients – read all about it.

COMPPARE Study Progress

Want the latest information on COMPPARE? Find out how many patients have enrolled and how many sites are currently enrolling patients on the COMPPARE Study Progress page.

Research reported in this newsletter was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-2017C1-0422). The views, statements, and opinions presented in this newsletter are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or Methodology Committee.